Pharmacoepidemiologic Studies Should Estimate AE Background Rates – FDA
• By The Pink Sheet
Pharmacoepidemiologic risk assessment by drug companies should include an estimate of background rates for the adverse event being studied, FDA said in its 1draft concept paper on pharmacovigilance
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
